Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257981 | 0.98 | POLG (0.46) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL3759574 | 0.91 | POLA1 (0.44) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL26102705 | 0.84 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18394211 | 0.83 | P2RY2 (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL30194983 | 0.83 | POLA1 (0.46) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL25396644 | 0.82 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL30697338 | 0.82 | P2RY2 (0.51) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL30140872 | 0.82 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL31337304 | 0.80 | POLG (0.47) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17215886 | 0.80 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113573736-B | Modified micrornas and their use in the treatment of cancer | 纽约州州立大学研究基金会 | 2025-03-25 | — | — | CN | disclosed |
| EP-3359163-B1 | COMBINATION THERAPY | NuCana plc (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230132256-A1 | COMBINATION THERAPY | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2023-04-27 | — | — | US | disclosed |
| WO-2022248268-A1 | COMBINATION THERAPY | ADC THERAPEUTICS SA (CH) | 2022-12-01 | — | — | WO | disclosed |
| US-20220323475-A1 | COMBINATION THERAPY FOR CANCER | NuCana plc (GB) | 2022-10-13 | — | — | US | disclosed |
| CN-113573736-A | Modified microRNAs and their use in the treatment of cancer | 纽约州州立大学研究基金会 | 2021-10-29 | — | — | CN | disclosed |
| EP-3820478-A1 | COMBINATION THERAPY | ADC Therapeutics SA (CH) | 2021-05-19 | — | — | EP | disclosed |
| CN-112367999-A | Combination therapy | ADC治疗有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200268783-A1 | COMBINATION THERAPY FOR CANCER | NuCana plc (GB) | 2020-08-27 | — | — | US | disclosed |
| US-10660912-B2 | Combination therapy for cancer | NuCana plc (GB) | 2020-05-26 | — | — | US | disclosed |
| WO-2020011724-A1 | COMBINATION THERAPY | ADC THERAPEUTICS SA (CH) | 2020-01-16 | — | — | WO | disclosed |
| US-20180271889-A1 | COMBINATION THERAPY FOR CANCER | NuCana plc (GB) | 2018-09-27 | — | — | US | disclosed |
| WO-2017060661-A1 | COMBINATION THERAPY | NUCANA BIOMED LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| US-20160058793-A1 | Tumor Targeted Sickle Erythroid Precursors, Progenitors and Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Microparticles and Liposomes for Treatment of Cancer | TERMAN DAVID S (US) | 2016-03-03 | — | — | US | disclosed |
| US-8388966-B2 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20090004200-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20060140962-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1372717-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030091574-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002076499-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132256-A1 | COMBINATION THERAPY | IL2RA, IL2, CD22 | POLG 1925/4885P2RY2 1253/4885P2RY4 1539/4885 |
| US-10660912-B2 | Combination therapy for cancer | TYMP, PNP, NUCB2 | POLG 29/4885P2RY2 1169/4885P2RY4 740/4885 |
| US-20180271889-A1 | COMBINATION THERAPY FOR CANCER | TYMP, PNP, NUCB2 | POLG 29/4885P2RY2 1169/4885P2RY4 740/4885 |
| US-20200268783-A1 | COMBINATION THERAPY FOR CANCER | TYMP, PNP, ENTPD5 | POLG 57/4885P2RY2 1114/4885P2RY4 833/4885 |
| US-20220323475-A1 | COMBINATION THERAPY FOR CANCER | TYMP, PNP, ENTPD5 | POLG 57/4885P2RY2 1114/4885P2RY4 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.